Coronary artery vasculopathy in pediatric cardiac transplant patients: The therapeutic potential of immunomodulators

Pediatric Drugs

Volumn 5, Issue 8, 2003, Pages 513-524

  Pietra, Biagio A ^a,b   Boucek, Mark M ^a  

^a CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ANTAGONIST; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL EXAMINATION; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REOPERATION; REVIEW; RISK FACTOR;

CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; GENE THERAPY; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041823430     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305080-00002     Document Type: Review

References (82)

1. Boucek MM, Faro A, Novick RJ, et al. The registry of the International Society of Heart and Lung Transplantation: third official pediatric report, 1999. J Heart Lung Transplant 1999; 18 (12): 1151-72
2. Pahl E. Transplant coronary artery disease in children. Prog Pediatr Cardiol 2000; 11: 137-43
3. Yun JJ, Fischbein MP, Laks H, et al. Chronic rejection of transplanted hearts. Curr Opin Organ Transplant 2001; 6: 205-10
4. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17 (8): 744-53
5. Wilhelm MJ, Pratschke J, Laskowski IA, et al. Brain death and its impact on the donor heart-lessons from animal models. J Heart Lung Transplant 2000; 19 (5): 414-8
6. Ardehali A, Laks H, Drinkwater Jr DC, et al. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. J Heart Lung Transplant 1993; 12 (6 Pt 1): 1044-51
7. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14 (6 Pt 2): S142-9
8. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261 (24): 3561-6
9. Mehra MR, Ventura HO, Smart FW, et al. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. J Heart Lung Transplant 1995; 14 (6 Pt 2): S246-9
10. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333 (10): 621-7
11. Kobashigawa J, Wener L, Johnson J, et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 2000; 19 (6): 546-50
12. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345 (22): 1593-600
13. Miner SE, Cole DE, Evrovski J, et al. Hyperhomocysteinemia and transplant coronary artery disease in cardiac transplant recipients. Clin Transplant 2001; 15 (4): 258-62
14. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997; 278 (14): 1169-75
15. Labarrere CA, Nelson DR, Park JW. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 2001; 16 (2): 110-7
16. Miller L, Kobashigawa J, Valantine H, et al. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. Sandoz/CVIS Investigators. J Heart Lung Transplant 1995; 14 (6 Pt 2): S227-34
17. Jutte NH, Groeneveld K, Balk AH, et al. The development of transplant coronary artery disease after cardiac transplantation is correlated with a predominance of CD8+ T lymphocytes in endomyocardial biopsy derived T cell cultures. Clin Exp Immunol 1994; 98 (1): 158-62
18. Nakagawa T, Sukhova GK, Rabkin E, et al. Acute rejection accelerates graft coronary disease in transplanted rabbit hearts. Circulation 1995; 92 (4): 987-93
19. Hosenpud JD, Everett JP, Morris TE, et al. Cardiac allograft vasculopathy: association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation 1995; 92 (2): 205-11
20. Mulla NF, Johnston JK, Vander Dussen L, et al. Late rejection is a predictor of transplant coronary artery disease in children. J Am Coll Cardiol 2001; 37 (1): 243-50
21. Russell PS, Chase CM, Winn HJ, et al. Coronary atherosclerosis in transplanted mouse hearts (II): importance of humoral immunity. J Immunol 1994; 152 (10): 5135-41
22. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97 (3): 833-8
23. Russell ME. Graft arteriosclerosis: molecular features of macrophage activation. Transplant Proc 1997; 29 (6): 2542-3
24. Tellides G, Tereb DA, Kirkiles-Smith NC, et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000; 403 (6766): 207-11
25. Pattison JM, Nelson PJ, Huie P, et al. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996; 15 (12): 1194-9
26. Yun JJ, Fischbein MP, Laks H, et al. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001; 71 (11): 1649-56
27. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105 (1): 35-44
28. Sata M, Luo Z, Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 2001; 166 (11): 6964-71
29. Hsu DT, Lamour JM, Korsin R, et al. Long term incidence of graft vasculopathy in children. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions; 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 173
30. Dent CL, Canter CE, Hirsch R, et al. Transplant coronary artery disease in pediatric heart transplant recipients. J Heart Lung Transplant 2000; 19 (3): 240-8
31. Dearani JA, Razzouk AJ, Gundry SR, et al. Pediatric cardiac retransplantation: intermediate-term results. Ann Thorac Surg 2001; 71 (1): 66-70
32. Fortuna RS, Chinnock RB, Bailey LL. Heart transplantation among 233 infants during the first six months of life: the Loma Linda experience. Loma Linda Pediatric Heart Transplant Group. Clin Transpl 1999: 263-72
33. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992; 11 (3 Pt 2): S38-44
34. Hirsch R, Balzer DT, Dent CL, et al. Outcome after diagnosis of moderate-severe transplant coronary artery disease (TCAD) in pediatric heart transplant recipients. J Heart Lung Transplant 2001; 20 (2): 261-2
35. Kuhn MA, Hashmi A, Deming DD, et al. Management of post-transplant coronary artery disease (PTCAD) using intravascular ultrasound (IVUS) improves outcome in pediatric heart transplant (htx) recipients. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 64
36. Pahl E, Duffy CE, Chaudhry FA. The role of stress echocardiography in children. Echocardiography 2000; 17 (5): 507-12
37. DiFilippo S, Roboisson M, Sassolas F, et al. Non-invasive detection of coronary artery disease by dobutamine stress echocardiography in children after heart transplant. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 83
38. Kobashigawa JA. Statins as immunosuppressive agents. Liver Transpl 2001; 7 (6): 559-61
39. Pietra BA, Wiseman A, Bolwerk A, et al. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 2000; 106 (8): 1003-10
40. Russell PS, Chase CM, Sykes M, et al. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 2001; 167 (10): 5731-40
41. Labarrere CA, Benner RW, Fuerst H, et al. Interleukin-1β and risk of coronary artery disease in heart transplant patients. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions: 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 59
42. Densem CG, Hutchinson IV, Yonan N, et al. Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 2001; 20 (12): 1265-73
43. Rose EA, Smith CR, Petrossian GA, et al. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 1989; 106 (2): 203-7
44. Rose ML. Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy. J Heart Lung Transplant 1996; 15 (4): 342-9
45. Leendert PC. Current controversies in cardiac transplantation: calcium channel blockers and angiotensin-converting enzyme inhibitors in the prevention of graft vasculopathy. J Heart Lung Transplant 2000; 19 (5): 409-13
46. Ballantyne CM. Statins after cardiac transplantation: which statin, what dose, and how low should we go. J Heart Lung Transplant 2000; 19 (6): 515-7
47. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6 (12): 1399-402
48. Labarrere CA, Nelson DR, Faulk WP. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 1998; 105 (3): 207-13
49. Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000; 284 (4): 457-64
50. Faulk WP, Labarrere CA. Modulation of vascular antithrombin III in human cardiac allografts. Haemostasis 1993; 23 Suppl. 1: 194-201
51. Aziz S, Tada Y, Gordon D, et al. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J Heart Lung Transplant 1993; 12 (4): 634-43
52. Teranishi K, Poston RS, Reitz BA, et al. Effect of low molecular weight heparin on suppression of chronic graft vascular disease in a rat cardiac allograft model. Transplant Proc 1998; 30 (4): 1009-11
53. Schlaifer JD, Mills RM. Effect of low molecular weight heparin on coronary endothelial function in acute cellular heart transplant rejection. Am J Cardiol 2000; 86 (1): 117-20
54. Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J 1994; 15 (9): 1191-5
55. Cooke GE, Eaton GM, Whitby G, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol 2000; 36 (2): 509-16
56. Jourdheuil-Rahmani D, Rolland PH, Rosset E, et al. Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc Res 1997; 34 (3): 597-602
57. Potena L, Grigioni F, Viggiani M, et al. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant 2001; 20 (12): 1245-51
58. Pethig K, Hoffmann A, Heublein B, et al. Cardiac allograft vascular disease after orthotopic heart transplantation: methylenetetrahydrofolate reductase gene polymorphism C677T does not account for rapidly progressive forms. Transplantation 2000; 69 (3): 442-5
59. Cook RC, Parker S, Kingsbury K, et al. Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. J Heart Lung Transplant 2001; 20 (3): 310-5
60. Miner SE, Cole DE, Evrovski J, et al. Pyridoxine improves endothelial function in cardiac transplant recipients. J Heart Lung Transplant 2001; 20 (9): 964-9
61. Parisi F, Kost-Byerly S, Saponara I, et al. Elevated plasma homocysteine concentrations after pediatric heart transplantations. Transpl Int 2000; 13 Suppl. 1: S235-9
62. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359 (9312): 1108-13
63. Wu GD, Jin Y-S, Barr ML, et al. Vascular endothelial cell apoptosis induced by non-MHC alloantibodies: an important injury mechanism in the development of chronic graft rejection. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 72
64. Miniati DN, Lijkwan MA, Murata S, et al. Adenoviral upregulation of Bcl-2 decreases oxidative stress and graft coronary artery disease in rat heart transplants. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 71
65. Cantin B, Gao SZ, Kwok BWK, et al. Mild cardiac allograft coronary disease does not change the prognosis of patients after heart transplantation. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 89
66. Cantin B, Gao SZ, Kwok BWK, et al. Prognosis of patients with significant angiographically diagnosed cardiac allograft coronary disease. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 96
67. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3 (4): 342-51
68. Dipchand AI, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5 (2): 112-8
69. Gao SZ, Kwok BWK, Cantin B, et al. Does late switch to mycophenolate mofetil affect development of transplant coronary artery disease. In: Kirklin JK, editor. The International Society for Heart and Lung Transplantation 22nd Annual Meeting and Scientific Sessions. 2002 Apr 10-13; Washington, DC: Elsevier, 2002: 89
70. Dipchand AI, Pietra B, McCrindle BW, et al. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001; 20 (10): 1035-43
71. Schutz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30 (4): 1185-7
72. Gregory CR. Immunosuppressive approaches to the prevention of graft vascular disease. Transplant Proc 1998; 30 (3): 878-80
73. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100 (1): 67-74
74. Braun-Dullaeus RC, Mann MJ, Seay U, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001; 21 (7): 1152-8
75. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104 (17): 2007-11
76. Paul LC. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation 2001; 71 (11 Suppl.): SS17-23
77. Kahan BD. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation 2001; 71 (11 Suppl.): SS52-7
78. Straatman LP, Coles JG. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70 (3): 541-3
79. Pappas PA, Weppler D, Pinna AD, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000; 4 (1): 45-9
80. Kaplan B, Meier-Kriesche HU, Napoli KL, et al. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients. Ther Drug Monit 1999; 21 (1): 44-9
81. Trepanier DJ, Gallant H, Legatt DF, et al. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998; 31 (5): 345-51
82. Shaddy RE, Revenaugh JA, Orsmond GS, et al. Coronary interventional procedures in pediatric heart transplant recipients with cardiac allograft vasculopathy. Am J Cardiol 2000; 85 (11): 1370-2